Great interview by one of our Scientific Advisory Board members, Dr. Oliver Sartor, who sat down with Dr. Philippe Legenne to discuss radioligand therapy using #DARPins and lead-212. Catch the full conversation here:

Major milestone: Mayo Clinic has treated the first U.S. patient in a clinical trial using Ac-225 for ER+/HER2- metastatic breast cancer. #RLT #ClinicalTrial #Ac255 #Radiopharmaceuticals.

Did you miss our latest announcement? We just launched a new first-of-its-kind infusion system designed specifically for the administration of #radiotherapies. #Radiopharmaceuticals #RLT #NucMed #Theranostics #Oncology #CancerCare.

Thanks to everyone who joined us for our July 2025 webinar about #CMC with Facet Life Sciences. Couldn’t make it live? The full recording is now available:

New data presented by Dr. Gokce Bilgin of @MayoClinic shows that retreatment with Lu-177 PSMA-617 may offer survival benefits for patients with #mCRPC who progress after initial therapy. #Radiopharmaceuticals #Lu177 #PSMA #NucMed.

#Techtransfer doesn’t have to be a bottleneck. #Radiopharmaceutical programs often hit delays when moving into #cGMP. Our whitepaper in Fierce Pharma explores how a staged, development-first model can reduce friction and accelerate progress.

Join Nucleus RadioPharma and Facet Life Sciences on Thursday, July 10th, at 9 AM CST for a discussion on the Chemistry, Manufacturing, and Controls (CMC) hurdles that can make or break your path to IND. #Radiopharmaceuticals #RLT #CDMO.

We’ve built something the radiopharma world has been missing: the first infusion system engineered specifically for radiopharmaceutical therapies. Our blog post explains it all: . #Radiopharmaceuticals #InfusionSystem #CDMO #RLT.

Join us and Facet Life Sciences on Thursday, July 10 at 9 AM CST for a joint webinar that unpacks the real-world considerations of scaling radiopharmaceuticals from R&D through regulatory submission. Register here: #Radiopharmaceuticals #RLT #Theranostics.

At Nucleus RadioPharma, we're developing a purpose-built, first-of-its-kind infusion system for radiopharmaceuticals. Learn all about the system in Fierce Pharma:. #Radiopharmaceuticals #Theranostics

Are you asking the right questions to keep your radiotherapy on track?. This guide breaks down what to ask, what to plan for, and how to avoid setbacks across R&D, clinical, manufacturing, and delivery.

Who else is getting excited for Society of Nuclear Medicine and Molecular Imaging (SNMMI)'s Annual Meeting? Our team will be in attendance! . ✉️ Reach out to BD@nucleusrad.com to set up a time to meet. We hope to see you there!. #SNMMI25 #SNMMI2025 #Radiopharmaceuticals #SNMMI

We’re thrilled to share that we have partnered with Facet Life Sciences to accelerate the development of novel radiopharmaceutical therapies. Full announcement:

A recent publication in the European Journal of Nuclear Medicine and Molecular Imaging presents the first clinical experience with [203/212Pb]Pb-VMT-α-NET, a novel theranostic agent targeting SSTR2-expressing neuroendocrine tumors (NETs). Check it out.

Scaling a therapy takes more than space. It takes timing, infrastructure, and a plan (long before commercialization). Learn why it needs to be part of your strategy from day one: . #Radiopharmaceuticals #RLT #Theranostics.

ICYMI: published an insightful article on a wide range of hurdles both small and large biopharmaceutical companies must overcome to bring their innovations forward. See our CCO, Kathy Spencer-Pike, comments by viewing the link.

We're excited to spotlight Ancora, a new tool launched by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) that’s making it easier than ever to connect with clinical trials in #radiopharmaceuticals. Explore Ancora here:

Fascinating look from AuntMinnie at eight promising alpha-emitting radionuclides, from actinium-225 to lead-212. #Radiopharmaceuticals #Ac225 #Lead212 #TAT.

Insights from Pharma Technology Focus: #Radiopharmaceutical science is advancing, the market is responding, but the infrastructure needs to catch up. Staying competitive means thinking about logistics, partnerships, and long-term scalability.

Bringing a radiopharmaceutical therapy to market is just the .beginning. What does it take to get your therapy delivered and administered properly? . Find out here: #Radiopharmaceuticals #RLT.